Getting The Deal Through logo
Getting The Deal Through


EU Parliament backs new health technology assessment legislation

Pharma - News – 10 October 2018

The European Parliament has approved a report from the EU’s Environment, Public Health and Food Safety Committee (ENVI) calling for the introduction of new health technology assessment (HTA) rules across the bloc.


No scope for appeal in UCB/Chugai patent dispute, English judge rules

Pharma - News – 10 October 2018

An English judge has largely dismissed Belgian pharmaceutical company UCB’s draft grounds for appeal after it lost a patent litigation against Japan’s Chugai Pharmaceutical in August.


AmerisourceBergen pays DoJ US$625m over repackaging claims

Pharma - News – 10 October 2018

US drug wholesaler AmerisourceBergen and four of its subsidiaries have struck a deal with the Department of Justice to settle claims they illegally pooled and repackaged cancer drugs.  


Court clears Fresenius to end Akorn acquisition

Pharma - News – 10 October 2018

A US judge has allowed Fresenius to scrap its planned $4.75 billion takeover of generic drugmaker Akorn, finding that the German healthcare company didn’t breach its merger agreement by pulling out of the deal after the target made false representations about the state of its data.


The PLN Round-up (10 October)

Pharma - The Round-up – 10 October 2018

News in brief from around the world… The UK’s medicines regulator has launched new hard Brexit consultations in the past week and the EMA is at work on revisions to its transparency rules. In the US, the Obama administration’s Health and Human Services deputy general counsel has returned to private practice and the Supreme Court has declined to hear an appeal on clinical trial liability. 


EU court throws out orphan drugmaker’s challenge to EMA disclosure

Pharma - News – 02 October 2018

The General Court of the European Union has dismissed an Anglo-American orphan drug company’s bid to block the European Medicines Agency from releasing a clinical study report for one of its treatments, finding the information wasn’t protected by EU rules on access to documents.






Follow Getting the Deal Through for the latest updates on law and regulation worldwide

Follow us on LinkedIn